loading...| Preferred Name |
isotretinoin |
|
| Synonyms |
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)2cis-4-trans-6-trans-8-trans-nonatetraenoic Acid |
|
| Definitions |
A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C603" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C603" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042657 |
|
| altLabel |
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)2cis-4-trans-6-trans-8-trans-nonatetraenoic Acid Oratane Isotrexin Roacutan Amnesteem 13-cis-retinoic acid Retinoicacid-13-cis 13-cis-vitamin A acid Neovitamin A Acid Claravis neovitamin A cis-retinoic acid Roaccutan Roaccutane Sotret 13-cis Retinoic Acid 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic Acid isotretinoinum Ro-4-3780 Cistane Accutane Accure Isotrex Ro 4-3780 13-CRA |
|
| CAS Registry |
4759-48-2 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000403149 http://purl.bioontology.org/ontology/PDQ/CDR0000038345 http://purl.bioontology.org/ontology/PDQ/CDR0000043215 http://purl.bioontology.org/ontology/PDQ/CDR0000433523 http://purl.bioontology.org/ontology/PDQ/CDR0000042447 http://purl.bioontology.org/ontology/PDQ/CDR0000042993 http://purl.bioontology.org/ontology/PDQ/CDR0000038546 http://purl.bioontology.org/ontology/PDQ/CDR0000433525 http://purl.bioontology.org/ontology/PDQ/CDR0000038429 http://purl.bioontology.org/ontology/PDQ/CDR0000038470 http://purl.bioontology.org/ontology/PDQ/CDR0000038639 http://purl.bioontology.org/ontology/PDQ/CDR0000363635 http://purl.bioontology.org/ontology/PDQ/CDR0000043450 http://purl.bioontology.org/ontology/PDQ/CDR0000041851 http://purl.bioontology.org/ontology/PDQ/CDR0000042148 http://purl.bioontology.org/ontology/PDQ/CDR0000042246 http://purl.bioontology.org/ontology/PDQ/CDR0000042207 http://purl.bioontology.org/ontology/PDQ/CDR0000038471 http://purl.bioontology.org/ontology/PDQ/CDR0000042247 http://purl.bioontology.org/ontology/PDQ/CDR0000041020 http://purl.bioontology.org/ontology/PDQ/CDR0000037957 |
|
| cui |
C1517611 C1517610 C0731265 C1330059 C0699581 C0594487 C1517612 C0022265 C0301727 C0701216 C1331177 C1521727 C1330536 C1517609 C0592073 |
|
| Date last modified |
2010-06-09 |
|
| definition |
A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C603" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C603" NCI Thesaurus) |
|
| IND Code |
28104 |
|
| Legacy PDQ ID |
641 |
|
| LT |
TRD |
|
| NCI ID |
C603 |
|
| notation |
CDR0000042657 |
|
| NSC Code |
329481 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
isotretinoin |
|
| tui |
T109 T127 T121 |